Neumora Therapeutics, Inc. financial data

Symbol
NMRA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 200, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.81K %
Debt-to-equity 6.04 %
Return On Equity -61.4 % -317%
Return On Assets -57.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 160M shares
Common Stock, Shares, Outstanding 159M shares +387%
Common Stock, Value, Issued 16K USD
Weighted Average Number of Shares Outstanding, Basic 159M shares +428%
Weighted Average Number of Shares Outstanding, Diluted 159M shares +428%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 175M USD +48.4%
General and Administrative Expense 56M USD +63.5%
Operating Income (Loss) -295M USD -51.7%
Nonoperating Income (Expense) 21M USD +49.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -58.6M USD -52%
Income Tax Expense (Benefit) 125K USD
Net Income (Loss) Attributable to Parent -274M USD -108%
Earnings Per Share, Basic -1.84 USD/shares +71.1%
Earnings Per Share, Diluted -1.84 USD/shares +71.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 151M USD -26.2%
Marketable Securities, Current 221M USD
Assets, Current 398M USD
Property, Plant and Equipment, Net 1.48M USD
Operating Lease, Right-of-Use Asset 3.47M USD
Assets 404M USD
Accounts Payable, Current 1.08M USD
Employee-related Liabilities, Current 7.46M USD
Accrued Liabilities, Current 18.3M USD
Liabilities, Current 23.1M USD
Operating Lease, Liability, Noncurrent 938K USD
Liabilities 23.2M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -187K USD
Retained Earnings (Accumulated Deficit) -816M USD
Stockholders' Equity Attributable to Parent 381M USD
Liabilities and Equity 404M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43M USD -30%
Net Cash Provided by (Used in) Financing Activities 1.85M USD +1727%
Net Cash Provided by (Used in) Investing Activities -150M USD -5425%
Common Stock, Shares Authorized 700M shares -42.1%
Common Stock, Shares, Issued 159M shares +387%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -191M USD -534%
Deferred Tax Assets, Valuation Allowance 197M USD +39.4%
Deferred Tax Assets, Gross 199M USD +38.4%
Operating Lease, Liability 5.23M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -274M USD -51.8%
Lessee, Operating Lease, Liability, to be Paid 5.61M USD
Property, Plant and Equipment, Gross 3.18M USD +7.68%
Operating Lease, Liability, Current 3.61M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.89M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.72M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 380K USD
Deferred Tax Assets, Operating Loss Carryforwards 79.1M USD +23.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 8.66M USD +5.97%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 158K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 1.5M USD -28.3%
Share-based Payment Arrangement, Expense 32.6M USD +402%